This is a StreetInsider.com Premium Only Page

(VRNA) – StreetInsider.com Reports

Apr 16, 2024 06:39 AM Verona Pharma (VRNA) PT Raised to $36 at Piper Sandler

Feb 29, 2024 06:32 AM Verona Pharma plc (VRNA) Tops Q4 EPS by 1c

Feb 1, 2024 05:45 AM Verona (VRNA) Appoints Michael Austwick as Non-Executive Director

Jan 2, 2024 04:37 AM Verona Pharma plc (VRNA) Enters $400M Debt Facility with Oxford Finance and Hercules Capital

Nov 2, 2023 04:25 AM Verona Pharma plc (VRNA) Tops Q3 EPS by 1c

Sep 11, 2023 05:41 AM Verona Pharma plc (VRNA) Announces FDA Accepted the NDA Filing for Ensifentrine for the Maintenance Treatment of COPD

Aug 31, 2023 05:51 AM Verona Pharma plc (VRNA) Appoints Christina Ackermann to its Board

Aug 4, 2023 08:38 AM Verona Pharma (VRNA) PT Raised to $35 at Canaccord Genuity

Aug 3, 2023 03:27 AM Verona Pharma plc (VRNA) Tops Q2 EPS by 2c

Jun 28, 2023 05:24 AM Verona Pharma plc (VRNA) Reports Publication of Phase 3 ENHANCE Data

Jun 7, 2023 07:07 AM Verona Pharma (VRNA) PT Raised to $32 at Truist Securities

May 22, 2023 07:50 AM Verona Pharma (VRNA) PT Raised to $38 at Jefferies

May 9, 2023 06:15 AM Verona Pharma plc (VRNA) Tops Q1 EPS by 8c

Mar 9, 2023 07:28 AM Verona Pharma (VRNA) PT Raised to $31 at Canaccord Genuity

Mar 7, 2023 06:22 AM Verona Pharma plc (VRNA) Misses Q4 EPS by 3c

Dec 21, 2022 06:43 AM Verona Pharma (VRNA) PT Raised to $32 at H.C. Wainwright

Dec 20, 2022 12:49 PM Verona Pharma (VRNA) PT Raised to $33 at Jefferies following positive data

Dec 20, 2022 12:14 PM Verona Pharma (VRNA) PT Raised to $30 at Wedbush following ensifentrine data

Dec 20, 2022 10:01 AM Verona Pharma (VRNA) PT Raised to $28 at Truist Securities

Dec 20, 2022 09:57 AM Verona Pharma (VRNA) PT Raised to $26 at BTIG following data

Dec 20, 2022 06:37 AM Verona Pharma plc (VRNA) surges 26% on positive COPD late-state trial data

Dec 20, 2022 04:02 AM Verona Pharma (VRNA) Reports Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial

Dec 19, 2022 04:02 PM Verona Pharma plc (VRNA) set to report top-line Phase 3 data from its ENHANCE-1 trial

Oct 17, 2022 05:25 AM Verona Pharma plc (VRNA) Announces $150M Debt Financing from Oxford Finance

Oct 14, 2022 05:23 AM Verona Pharma (VRNA) Reports Phase 3 Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups

Sep 19, 2022 06:40 AM Wedbush Assumes Verona Pharma (VRNA) at Outperform

Aug 29, 2022 06:37 AM UPDATE: Verona Pharma (VRNA) PT Raised to $30 at H.C. Wainwright

Aug 26, 2022 06:21 AM UPDATE: Piper Sandler Starts Verona Pharma (VRNA) at Overweight

Aug 24, 2022 05:18 AM Verona Pharma plc (VRNA) Announces Additional Commercialization Team Appointments

Aug 11, 2022 05:35 AM Verona Pharma plc (VRNA) Pricing Upsized 12.4M Share Offering at $10.50/sh

Aug 10, 2022 08:44 AM Verona Pharma (VRNA) PT Raised to $20 at Truist Securities

Aug 9, 2022 04:19 PM Verona Pharma plc (VRNA) Announces Proposed Stock Offering

Aug 9, 2022 06:24 AM Verona Pharma plc (VRNA) Reports Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial

Jun 22, 2022 07:30 AM "We're Positive Into Ph3 Ensifentrine Data In August" - Truist Securities Bullish on Verona Pharma (VRNA) Ahead of Key Readout

May 3, 2022 10:11 AM Truist Securities Reiterates Buy Rating on Verona Pharma (VRNA), Sees "High Probability of Success" of ensifentrine in Phase 3

May 3, 2022 05:55 AM Verona Pharma plc (VRNA) Reports Q1 Results, Provides Corporate Update

Mar 4, 2022 08:27 AM Truist Securities Reiterates Verona Pharma (VRNA) at Buy, "We Like Risk/Benefit Heading into Phase 3 Readout"

Dec 16, 2021 05:57 AM Verona Pharma plc (VRNA) Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction

Nov 12, 2021 07:56 AM Verona Pharma (VRNA) PT Raised to $23 at Canaccord Genuity

Sep 13, 2021 06:13 AM H.C. Wainwright Starts Verona Pharma (VRNA) at Buy

May 3, 2021 08:15 AM Verona Pharma (VRNA) PT Lowered to $18 at Canaccord Genuity

Apr 27, 2021 05:55 AM Verona Pharma plc (VRNA) Reports Publication of Phase 2b Dose-Ranging COPD Data

Mar 2, 2021 04:05 PM Verona Pharma (VRNA) PT Raised to $19 at Canaccord Genuity

Feb 2, 2021 05:55 AM Verona Pharma plc (VRNA) Announces Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COP

Sep 23, 2020 01:14 PM Verona Pharma plc (VRP:LN) (VRNA) PT Raised to $25 at Wedbush, After Company Initializes Phase 3 Trials

Sep 23, 2020 05:50 AM Verona Pharma plc (VRNA) Begins Phase 3 Clinical Trials with Nebulized Ensifentrine for Maintenance Treatment of COPD

Sep 16, 2020 08:26 AM Verona Pharma (VRNA) Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease

Sep 8, 2020 06:28 AM Verona Pharma plc (VRNA) Begins Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

Aug 25, 2020 04:53 AM UPDATE: Jefferies Assumes Verona Pharma (VRNA) at Buy

Aug 19, 2020 06:18 AM Verona Pharma plc (VRNA) Begins Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD